# Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

> **NCT03131908** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Melanoma and Other Malignant Neoplasms of Skin
- Metastatic Melanoma

## Interventions

- **DRUG:** GSK2636771
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03131908
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131908, "Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03131908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*